Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Vertex Pharmaceuticals Incorporated
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary == Vertex Pharmaceuticals Incorporated, a leading biotechnology firm, specialises in the development and commercialization of innovative therapies for the treatment of cystic fibrosis. Since its inception in 1989, Vertex Pharmaceuticals has been at the forefront of biotechnological advancements. The company is headquartered in Boston, Massachusetts, where it continues to make strides in developing life-altering therapies. The company's groundbreaking products include SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, all aimed at treating cystic fibrosis patients with specific mutations in their cystic fibrosis transmembrane conductance regulator gene. TRIKAFTA is particularly beneficial for patients aged 6 years and above who carry at least one F508del mutation.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)